Business, Free News Articles, Funding and Investment

Proteios Technology, Inc. Awarded $1.6 Million NIH SBIR Grant to Commercialize its Multivariate Cell Isolation Technology

SEATTLE, Wash. -- Proteios Technology, Inc. is pleased to announce it's received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios' cell isolation kits to include up to 20 of the most common cell types currently used in cell therapy development.

Cell biology is complex. And conducting experiments on an isolated population of cells, rather than a heterogeneous mix, is a common approach to reduce experimental complexity. Cell isolation allows cell biologists to confidently attribute observed effects and responses to a particular cell type.

Specifically, Proteios' multivariate cell isolation technology provides high-performance, antibody- and magnetic bead-free isolation of cell types in fewer than 30 minutes. This is a big reduction in time compared to currently available methods, while meeting or exceeding cell yield, purity and viability.

Proprietary Proteios Chimeras will be designed and developed to bind to each of the 20 target cell types with high specificity and selectivity through a combination of robotic biological screening, Machine Learning (ML) and Molecular Dynamics (MD) simulation.

Proteios will also incorporate Proteios Chimeras into its cGMP cell therapy manufacturing device - a bench prototype funded under contract by the National Cancer Institute (NCI). The device provides end-to-end manufacturing of cell therapies in a closed and fully-automated system with concise control over the multiple cell types that form the basis of cell therapy formulations. Proteios Chimeras will be a major component of consumables for the cGMP cell therapy manufacturing device.

"It's believed that the effectiveness of cellular therapeutics can be improved by the addition/removal of certain secondary cell types," Bob Snyder, Ph.D., co-founder and CEO of Proteios Technology, says. "Proteios' cell isolation technology will provide for the parallel enrichment and/or depletion of any cell type as new cell therapy formulations are investigated, reducing the vein-to-vein time and overall manufacturing cost."

Proteios is also preparing for the immediate commercial release of its research-scale recombinant protein purification kits which will provide a viable alternative to His Tag technology, unusable with about 20 percent of proteins of interest.

Initially, Proteios will launch two kits based on a proprietary affinity tag and a silica-based resin for:

1 - high-expressing proteins; and

2 - low-expressing proteins.

To learn more:

About Proteios Technology:

Proteios Technology is a leading provider of products and services dedicated to supporting the discovery of advanced therapeutics and their efficient manufacturing. Its innovative solutions support research at all levels from discovery and translational research to cGMP manufacturing and companion diagnostics. Its technologies enable the multivariate (parallel), tag-free isolation of any biological, including proteins/biopharmaceuticals, cell types, antibodies and viruses. Proteios' research-scale kits enable the discovery of new advanced therapeutics. And the inherent scalability of the technology allows the same methodology to be used in the manufacturing of advanced therapeutics and dramatically reduces the time required for process development.

Proteios is driven by the goal to lower the cost of healthcare and to provide advanced therapeutics to a larger patient population. It's located in the heart of Seattle and adjacent to some of the world's leading cell therapy research institutes - including the Fred Hutchinson Cancer Research Center, Seattle Children's Research Institute and the Seattle Cancer Care Alliance.

Related link:

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Manufacturing

End-to-end transport Solution for Medical therapies and Products Relying on Cold Chain: Secure, Traceable, Reusable

LOS ANGELES, Calif. -- Southern California based Mergers and Acquisitions firm ProNova Partners has been commissioned to facilitate investment in or the sale of a patented, groundbreaking packaging technology. The technology facilitates a secure, traceable, and reusable end-to-end transport solution for expensive medical therapies and products that rely on the cold chain.

17-year-old Mergers and Acquisitions firm, ProNova Partners, has announced their commission to facilitate the manufacture and sale of a patented, portable refrigerator and freezer that provides remote tracking, monitoring and Chain-of-Custody for therapeutics and vaccines.

It protects temperature sensitive medical therapeutics such as COVID-19 Vaccines and Biological and Cellular Therapies including controlled substances that are being distributed and need to be stored at remote, last mile locations. It can be used for Clinical Trials, Home Infusion, Compounding Pharmacies delivering to the home, Academic Research Laboratories and Consumer applications.

"This new technology will save lives in both developed and emerging countries," announced Rick Carlson CEO and founder of ProNova Partners. "We are proud to be a part of bringing this to the world market."

ProNova Partners has assisted expansion or sale of some 400 firms in its history, in multiple areas of the marketplace. "We are very gratified to be able to lend a hand in the movement of great technology such as this into the market."

The technology has resulted in the smallest, most portable "cold chain" system available, with the longest autonomy time between recharges (>96hrs). It has been built for durability and reliability by the best thermal engineers on the planet. Designed for both transport in an airline cabin or as air cargo freight, it is an all-in-one solution that provides security, real-time alerts, and traceability for temperature sensitive medical products. The system has controlled room temperature, plus refrigerated and frozen set points. It has dual heat and cool modes and is based on a military grade, micro refrigeration compressor.

"This system enables better health care delivery by making the cold chain possible in places where there is limited to no cold chain or electrical infrastructure," concluded Carlson. "By utilizing less than 2 W/Hr, it can easily be recharged with a small solar panel."

For detailed information go to:

Related link:

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022